LAG3 anticorps (N-Term)
-
- Antigène Voir toutes LAG3 Anticorps
- LAG3 (Lymphocyte-Activation Gene 3 (LAG3))
-
Épitope
- N-Term
-
Reactivité
- Humain
-
Hôte
- Souris
-
Clonalité
- Monoclonal
-
Conjugué
- Cet anticorp LAG3 est non-conjugé
-
Application
- Western Blotting (WB), ELISA, Immunohistochemistry (IHC), Flow Cytometry (FACS), Immunocytochemistry (ICC), Immunoprecipitation (IP)
- Specificité
- Recognizes the 30 aa extra-loop of the first N-terminal D1 domain of LAG-3.
- Attributs du produit
- Lymphocyte activation gene-3| FDC protein| CD223,LAG-3 (human) recombinant monoclonal antibody (L4-PL33)
- Purification
- Purified.,Purified from tissue culture supernatant.
- Immunogène
- Synthetic peptide corresponding to 30 aa (GPPAAAPGHPLAPGPHPAAPSSWGPRPRRY) from the first N-terminal D1 domain of human LAG-3 (lymphocyte activation gene-3).
- Clone
- L4-PL33
- Isotype
- IgG1 kappa
- Top Product
- Discover our top product LAG3 Anticorps primaire
-
-
- Indications d'application
- Immunohistochemistry (frozen sections, 1:150)Western Blot (5 μg/mL)Immunoprecipitation (10 μg/mL)Suggested dilutions/conditions may not be available for all applications.Optimal conditions must be determined individually for each application.
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Buffer
- Liquid. In PBS containing 10 % glycerol and 0.02 % sodium azide.
- Agent conservateur
- Sodium azide
- Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Conseil sur la manipulation
- Avoid freeze/thaw cycles.
- Stock
- -20 °C
- Stockage commentaire
- +4°C Stable for at least 6 months after receipt when stored as recommended.
- Date de péremption
- 6 months
-
- Antigène
- LAG3 (Lymphocyte-Activation Gene 3 (LAG3))
- Autre désignation
- LAG-3 (LAG3 Produits)
- Synonymes
- anticorps CD223, anticorps LAG-3, anticorps Ly66, anticorps lymphocyte activating 3, anticorps lymphocyte-activation gene 3, anticorps LAG3, anticorps Lag3
- UniProt
- P18627
- Pathways
- Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints
-